Drug intelligence / Profile preview

Qixian Qingming Granules

Development stage: Unknown
Administration: Oral

Overview

Qixian Qingming Granules (芪仙清鸣颗粒) is a traditional Chinese medicine (TCM) formulation. It is presented as granules for oral administration. The specific composition, mechanism of action, and primary indications are not detailed in the available sources. Based on the naming convention and typical TCM practice, it likely contains Astragalus (黄芪, "Qi") as a principal ingredient and may be used for respiratory or immune-related conditions; however, no direct evidence or official documentation confirming its ingredients or clinical use was found in the provided search results.

Brand names: Qixian Qingming Granules
Other names: 芪仙清鸣颗粒

Targets

BCL-2 (BCL-2 family)NFKB1 (NF-κB1)EGFR T790M (Epidermal growth factor receptor T790M mutant)CASP3 (Caspase-3)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on Qixian Qingming Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qixian Qingming Granules.

Explore the full profile